Racial differences in the use of adjunctive psychotropic medications for patients with Schizophrenia

Journal of Mental Health Policy and Economics

Volumn 10, Issue 1, 2007, Pages 15-22

  Mallinger, Julie B ^a,c   Lamberti, Steven J ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DIAZEPAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LITHIUM; LORAZEPAM; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; PSYCHOTROPIC AGENT; SERTRALINE; TRAZODONE; VALPROIC ACID; VENLAFAXINE;

ADJUVANT THERAPY; ADULT; ARTICLE; BIVARIATE ANALYSIS; CAUCASIAN; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; FEMALE; HEALTH CARE ACCESS; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEGRO; RACE DIFFERENCE; SCHIZOPHRENIA; UNITED STATES; UNIVARIATE ANALYSIS;

ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEMOGRAPHY; DRUG THERAPY; DRUG THERAPY, COMBINATION; ETHNIC GROUPS; FEMALE; HUMANS; MALE; PREVALENCE; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA;

EID: 34247266575     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Kreyenbuhl J, Zito JM, Buchanan RW, Soeken KL, Lehman AF. Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull 2003; 29: 183-193.
2. Siris SG. Depression in schizophrenia: perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry 2000; 157: 1379-1389.
3. Martin RL, Cloninger CR, Guze SB, Clayton PJ. Frequency and differential diagnosis of depressive syndromes in schizophrenia. J Clin Psychiatry 1985; 46: 9-13.
4. Keck PE, Jr., Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry 2000; 61: 4-9.
5. Harrow M, Yonan CA, Sands JR, Marengo J. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophr Bull 1994; 20: 327-338.
6. Dixon L, Green-Paden L, Delahanty J, Lucksted A, Postrado L, Hall J. Variables associated with disparities in treatment of patients with schizophrenia and comorbid mood and anxiety disorders. Psychiatr Serv 2001; 52: 1216-1222.
7. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 1999; 156: 1138-1148.
8. Carpenter WT, Jr., Buchanan RW, Kirkpatrick B, Breier AF. Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry 1999; 156: 299-303.
9. Clark RE, Xie H, Brunette MF. Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J Clin Psychiatry 2004; 65: 151-155.
10. Nestoros JN, Nair NP, Pulman JR, Schwartz G, Bloom D. High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients. Psychopharmacology (Berl) 1983; 81: 42-47.
11. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 1992; 31: 698-704.
12. Delahanty J, Ram R, Postrado L, Balis T, Green-Paden L, Dixon L. Differences in rates of depression in schizophrenia by race. Schizophr Bull 2001; 27: 29-38.
13. Johnson DA. The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry 1988; 152: 320-323.
14. Becker RE. Depression in schizophrenia. Hosp Community Psychiatry 1988; 39: 1269-1275.
15. Addington DE, Addington JM. Attempted suicide and depression in schizophrenia. Acta Psychiatr Scand 1992; 85: 288-291.
16. Schulz SC, Kahn EM, Baker RW, Conley RR. 1990. Lithium and carbamazepine augmentation in treatment-refractory schizophrenia. In The Neuroleptic-Non-responsive Patient: Characterization and Treatment. Washington, D.C.: American Psychiatric Press, 109-136.
17. Johns CA, Thompson JW. Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Schizophr Bull 1995; 21: 607-619.
18. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991; 17: 217-245.
19. Basan A, Kissling W, Leucht S. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophr Res 2004; 70: 33-37.
20. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J. Practice guidelines for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161: 1-56.
21. Kane JM. Schizophrenia. N Engl J Med 1996; 334: 34-41.
22. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991; 148: 714-726.
23. Herz MI, Lamberti JS. Prodromal symptoms and relapse prevention in schizophrenia. Schizophr Bull 1995; 21: 541-551.
24. Herrera JM, Alvarez WA, Freinhar JP, Lawson WB, Sramek JJ. Adjunctive clonazepam in the treatment of chronic schizophrenia. Int J Psychosom 1991; 38: 17-20.
25. Nestoros JN, Suranyi-Cadotte BE, Specs RC, Schwartz G, Nair NP. Diazepam in high doses is effective in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 513-516.
26. Brunette MF, Noordsy DL, Xie H, Drake RE. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv 2003; 54: 1395-1401.
27. Owen RR, Feng W, Thrush CR, Hudson TJ, Austen MA. Variations in prescribing practices for novel antipsychotic medications among Veterans Affairs Hospitals. Psychiatr Serv 2001; 52: 1523-1525.
28. Daumit GLM, Crum RMM, Guallar EM, Powe NRM, Primm ABM, Steinwachs DMP, Ford DEMM. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and Whites in the United States. Arch Gen Psychiatry 2003; 60: 121-128.
29. Copeland LA, Zeber JE, Valenstein M, Blow FC. Racial disparity in the use of atypical antipsychotic medications among veterans. Am J Psychiatry 2003; 160: 1817-1822.
30. Mark TL, Dirani R, Slade E, Russo PA. Access to new medications to treat schizophrenia. J Behav Health Serv Res 2002; 29: 15-29.
31. Kuno E, Rothbard AB. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry 2002; 159: 567-572.
32. Elk R, Dickman BJ, Teggin AF. Depression in schizophrenia: a study of prevalence and treatment. Br J Psychiatry 1986; 149: 228-229.
33. Glazer WM, Morgenstern H, Doucette J. Race and tardive dyskinesia among outpatients at a CMHC. Hosp Community Psychiatry 1994; 45: 38-42.
34. Lehman AF, Steinwachs DM. Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull 1998; 24: 11-20.
35. Sowers W, Golden S. Psychotropic medication management in persons with co-occurring psychiatric and substance use disorders. J Psychoactive Drugs 1999; 31: 59-70.
36. Rothbard AB, Kuno E, Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull 2003; 29: 531-540.
37. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19.
38. Rayburn TM, Stonecypher JF. Diagnostic differences related to age and race of involuntarily committed psychiatric patients. Psychol Rep 1996; 79: 881-882.
39. Leda C, Rosenheck R. Race in the treatment of homeless mentally ill veterans. J Nerv Ment Dis 1995; 183: 529-537.
40. Adebimpe VR. Overview: white norms and psychiatric diagnosis of black patients. Am J Psychiatry 1981; 138: 279-285.
41. Cooper-Patrick L, Gallo JJ, Powe NR, Steinwachs DM, Eaton WW, Ford DE. Mental health service utilization by African Americans and Whites: the Baltimore Epidemiologic Catchment Area Follow-Up. Med Care 1999; 37: 1034-1045.
42. Lasser KE, Himmelstein DU, Woolhandler SJ, McCormick D, Bor DH. Do minorities in the United States receive fewer mental health services than whites? Int J Health Serv 2002; 32: 567-578.
43. Kressin NR, Chang BH, Whittle J, Peterson ED, Clark JA, Rosen AK, Orner M, Collins TC, Alley LG, Petersen LA. Racial differences in cardiac catheterization as a function of patients' beliefs. Am J Public Health 2004; 94: 2091-2097.
44. Chung H, Mahler JC, Kakuma T. Racial differences in treatment of psychiatric inpatients. Psychiatr Serv 1995; 46: 586-591.